We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+37.22%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$29.1M
Cap. Flow
-$68.9M
Cap. Flow %
-23.29%
Top 10 Hldgs %
37.63%
Holding
99
New
29
Increased
28
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.19M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.21M
3
VRAY
ViewRay, Inc.
VRAY
+$5.34M
4
PLRX icon
Pliant Therapeutics
PLRX
+$4.01M
5
NKTX icon
Nkarta
NKTX
+$3.6M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.29M
2
APLS
Apellis Pharmaceuticals
APLS
+$5.87M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$4.91M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.34M
5
BIIB icon
Biogen
BIIB
+$4.25M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
26
Pliant Therapeutics
PLRX
$65M
$4.38M 1.48%
+209,822
New +$4.01M
ABOS icon
27
Acumen Pharmaceuticals
ABOS
$152M
$4.21M 1.43%
+420,000
New +$2.41M
KRYS icon
28
Krystal Biotech
KRYS
$10.7B
$3.95M 1.34%
56,645
-48,632
-46% -$3.51M
ORIC icon
29
Oric Pharmaceuticals
ORIC
$1.17B
$3.87M 1.31%
1,208,992
+126,688
+12% +$507K
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$123B
$3.21M 1.09%
11,105
+691
+7% +$199K
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.18M 1.08%
+177,364
New +$2.33M
MRTX
32
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.97M 1%
42,500
-58,400
-58% -$4.32M
CRNX icon
33
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.93M 0.99%
149,027
+9,488
+7% +$193K
RGNX icon
34
Regenxbio
RGNX
$616M
$2.91M 0.98%
110,085
+5,956
+6% +$177K
CGEM icon
35
Cullinan Oncology
CGEM
$1.06B
$2.88M 0.97%
224,555
+11,465
+5% +$154K
CVRX icon
36
CVRx
CVRX
$131M
$2.87M 0.97%
307,920
+15,775
+5% +$125K
LVTX
37
DELISTED
LAVA Therapeutics
LVTX
$2.79M 0.94%
+610,809
New +$1.68M
ALLK
38
DELISTED
Allakos
ALLK
$2.45M 0.83%
+400,000
New +$1.68M
MCRB icon
39
Seres Therapeutics
MCRB
$45M
$2.35M 0.8%
18,325
+937
+5% +$96K
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.42B
$2.35M 0.8%
186,603
+133,082
+249% +$1.71M
KRTX
41
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.32M 0.79%
+10,323
New +$2.09M
PNT
42
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$2.32M 0.78%
+300,000
New +$2.55M
UTHR icon
43
United Therapeutics
UTHR
$26.1B
$2.24M 0.76%
10,696
-5,531
-34% -$1.24M
PHR icon
44
Phreesia
PHR
$689M
$2.12M 0.72%
83,305
+5,194
+7% +$130K
ESPR
45
DELISTED
Esperion Therapeutics
ESPR
$2.1M 0.71%
+314,095
New +$2.16M
IMGN
46
DELISTED
Immunogen Inc
IMGN
$2.1M 0.71%
438,695
+22,216
+5% +$117K
ARVN icon
47
Arvinas
ARVN
$530M
$1.81M 0.61%
+40,741
New +$1.98M
NTLA icon
48
Intellia Therapeutics
NTLA
$1.51B
$1.79M 0.61%
+32,011
New +$1.99M
IMVT icon
49
Immunovant
IMVT
$7.93B
$1.67M 0.57%
+300,000
New +$1.47M
IMTX icon
50
Immatics
IMTX
$1.23B
$1.64M 0.55%
163,938
-191,165
-54% -$2.06M
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Silverarc Capital Management held 99 positions worth $296M, down 9% from $325M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management withdrew a net $68.9M in Q3 2022, closing 20 positions and reducing 20 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $5.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Alnylam Pharmaceuticals worth $6.51M.

  • Silverarc Capital Management's largest Q3 2022 buy was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M.
  • Silverarc Capital Management added most to Poseida Therapeutics, Inc. Common Stock in Q3 2022, an estimated $7.19M increase.
  • Silverarc Capital Management's biggest Q3 2022 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.29M.
  • Silverarc Capital Management fully exited Apellis Pharmaceuticals in Q3 2022, selling an estimated $5.87M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $296M portfolio in Q3 2022.
  • Silverarc Capital Management opened 29 new positions and closed 20 in Q3 2022.
  • Silverarc Capital Management's portfolio value fell 9% quarter-over-quarter to $296M.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.